Antiarrhythmic activity of n-tyrosol during acute myocardial ischemia and reperfusion. 2007

G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
Department of Circulation Pharmacology, State Research Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.

Antiarrhythmic activity of n-tyrosol was demonstrated on the model of early occlusion and reperfusion arrhythmia. The preparation reduces the incidence of ventricular tachycardia and fibrillation, increases the percent of animals without ventricular arrhythmia, and moderates the severity of developing ventricular arrhythmias.

UI MeSH Term Description Entries
D010626 Phenylethyl Alcohol An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery. Benzyl Carbinol,Phenethyl Alcohol,Phenylethanol,2-Phenylethanol,beta-Phenylethanol,2 Phenylethanol,Alcohol, Phenethyl,Alcohol, Phenylethyl,Carbinol, Benzyl,beta Phenylethanol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D014693 Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST. Fibrillation, Ventricular,Fibrillations, Ventricular,Ventricular Fibrillations
D015428 Myocardial Reperfusion Injury Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm. Reperfusion Injury, Myocardial,Injury, Myocardial Reperfusion,Myocardial Ischemic Reperfusion Injury,Injuries, Myocardial Reperfusion,Myocardial Reperfusion Injuries,Reperfusion Injuries, Myocardial
D017180 Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
April 1989, European journal of pharmacology,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
May 2015, Journal of cardiovascular pharmacology and therapeutics,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
February 1983, American heart journal,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
September 1998, Molecular and cellular biochemistry,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
May 1988, American heart journal,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
January 1997, Dimensions of critical care nursing : DCCN,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
January 1988, European journal of pharmacology,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
March 1990, Journal of cardiovascular pharmacology,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
August 1985, Biochemical medicine,
G A Chernyshova, and M B Plotnikov, and V I Smol'yakova, and I V Golubeva, and O I Aliev, and T G Tolstikova, and A P Krysin, and I V Sorokina
August 1995, The American journal of cardiology,
Copied contents to your clipboard!